News > Zydus Cadila launches breast cancer treatment drug Ujvira

Zydus Cadila launches breast cancer treatment drug Ujvira

The company has launched Trastuzumab Emtansine, the first antibody-drug conjugate (ADC) biosimilar and a highly effective drug for treating both early and advanced HER2 positive breast cancer, under the brand name Ujvira, Zydus Cadila said in a statement.

Zydus Cadila said HER2 positive breast cancer is considered an aggressive form and constitutes 20 to 25 percent of all breast cancers.